Fund Holdings — Patient Square Capital LP

Total Portfolio Value
$269.41M
Total Bought
$56.47M
Total Sold
$0
Net Transaction
+$56.47M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
CULLINAN THERAPEUTICS, INC.(CGEM)0824,705+824,705013,8065.12%+13,806
INSMED INC(INSM)0171,704+171,704012,5344.65%+12,534
ROIVANT SCIENCES LTD(ROIV)12,228,46512,228,4650129,255141,11652.38%+11,862
EYEPOINT PHARMACEUTICALS(EYPT)01,361,979+1,361,979010,8824.04%+10,882
NURIX THERAPEUTICS, INC.(NRIX)0325,789+325,78907,3202.72%+7,320
PHARVARIS N.V.
COM
0242,341+242,34104,4881.67%+4,488
INTELLIA THERAPEUTICS, INC.(NTLA)0128,569+128,56902,6420.98%+2,642
ENLIVEN THERAPEUTICS, INC.090,572+90,57202,3130.86%+2,313
OCULAR THERAPEUTIX, INC.(OCUL)0235,498+235,49802,0490.76%+2,049
ASTRIA THERAPEUTICS, INC.039,422+39,42204340.16%+434
LIQUIDIA CORPORATION(LQDA)7,182,5327,182,532086,19071,82526.66%-14,365
Page 1 of 1
Patient Square Capital LP — 13F Holdings — Q3 2024 | TickerTrail